Contact Us
INNOGLY INNOGLY INNOGLY INNOGLY
Navigation
  • About us
    • COST Action
    • Network members
    • Scientific Outputs
      • Scientific Publications
      • Abstracts from Events
  • News
  • Events
  • Working Groups
    • Development and Cancer
    • Autophagy
    • Immunity
    • GAGs
  • STSM
    • STSM information
    • STSM proposal
    • STSM evaluation
    • Awarded STSMs
  • ITC Grants
  • Training Schools

Logged out

Lost Password?

News

First Italian-American Symposium on Applied and Translational Glycosciences
  For participation in the Symposium registration to ACS Spring 2021 ...
Read More
Emerging glyco‐based strategies to steer immune responses
Abstract Glycan structures are common posttranslational modifications of proteins, which serve ...
Read More
Research Topic: Frontiers in Immunology
Urinary tract infections (UTIs) are among the most common bacterial ...
Read More
Call for Short Term Scientific Missions (STSMs) 2021
The 1st and the only call for the Short Term ...
Read More
WG1-WG3 Joint Meeting “Glycosylation in Cancer and Tumour Immunology”
Dates: 8th and 9th October 2020 i3S – Instituto de Investigação ...
Read More
Innogly review

Emerging glyco‐based strategies to steer immune responses

Abstract

Glycan structures are common posttranslational modifications of proteins, which serve multiple important structural roles (for instance in protein folding), but also are crucial participants in cell‐cell communications and in the regulation of immune responses. Through the interaction with glycan‐binding receptors glycans are able to affect the activation status of antigen presenting cells, leading to either induction of pro‐inflammatory responses or to suppression of immunity and instigation of immune tolerance. This unique feature of glycans has attracted the interest and spurred collaborations of glyco‐chemists and glyco‐immunologists to develop glycan‐based tools as potential therapeutic approaches in the fight against diseases such as cancer and autoimmune conditions. In this review we highlight emerging advances in this field, and in particular we discuss on how glycan‐modified conjugates or glycoengineered cells can be employed as targeting devices to direct tumor antigens to lectin receptors on antigen presenting cells, like dendritic cells. In addition, we address how glycan‐based nanoparticles can act as delivery platforms to enhance immune responses. Finally, we discuss some of the latest developments in glycan‐based therapies, including chimeric antigen receptor (CAR)‐T cells to achieve targeting of tumor‐associated glycan‐specific epitopes, as well as the use of glycan moieties to suppress ongoing immune responses, especially in the context of autoimmunity.

https://febs.onlinelibrary.wiley.com/doi/abs/10.1111/febs.15830

March 25, 2021

Events

First Italian-American Symposium on Applied and Translational Glycosciences
  For participation in the Symposium registration to ACS Spring 2021 ...
Read More
WG1-WG3 Joint Meeting “Glycosylation in Cancer and Tumour Immunology”
Dates: 8th and 9th October 2020 i3S – Instituto de Investigação ...
Read More
INNOGLY Virtual Training in GlycoAnalysis and GlycoInformatics 2nd-3rd of November 2020
Here the Final PDF: https://drive.google.com/file/d/1tF1RbLH_4y3-DzTccLjct8kWgyIqXomO/view?usp=sharing Monday- GlycoAnalysisCentral European Time (CET) 2-Nov 10-10.45 ...
Read More

Follow us on Twitter


Follow INNOGLY

Twitter Timeline

RT @MCGalan_Bristol: A Vibration‐Induced Emision‐Based Fluorescent Chemosensor for the Selective and Visual Recognition of Glucose https://…

RT @CzerwinsMarcin: Blood group databases: what should we know about them? A review by Jill R. Story, https://t.co/v1dtISiHW4

#blood_trans…

RT @CzerwinsMarcin: Interesting review: galectins as modulators of receptor tyrosine kinases signaling. How galectins interact with recepto…

RT @CarboMet_EU: Join us this Thursday (Apr 22nd) at 4 pm UK time where we will be joined by 2 fantastic speakers from the US in our first…

RT @RobertoAdamo10: I’m a believer of academia-industry collaboration. This week glyconeer has been installed in GSK. A discussion started…

POLICY STATEMENT:

Biomedicine and Molecular Biosciences Action CA18103 is funded by COST, which is supported by the EU Framework Programme Horizon 2020.

COST Action CA18103

© Copyright 2021. All Rights Reserved | Powered by innogly.eu | Designed by AWA
  • Imprint
  • /
  • Privacy policy
  • /

Cookies

This site uses cookies: Find out more.